Aevi Genomic Medicine — Medgenics — Q1 2016 Earnings Presentation
21 slides from Aevi Genomic Medicine's earnings presentation, May 10, 2016
Slide 1: Q1 2016 Results and Program Update
Q1 2016 Results and NFC - 1 Program Update May 10, 2016
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results
Slide 3: Agenda
Agenda • Executive Summary • NFC - 1 Development Program Update – Phenotype/genotype – Phase 2/3 adolescent – 22q Deletion Syndrome – Regulatory Update • mGluR + ADHD Opportunity • Q1 Results of Operations • 2016 Milestones • Summary 3
Slide 4: Executive Summary
Executive Summary • Enthusiastic initial response to our genomic medicine approach in ADHD from physicians and patients • Rapid enrollment into phenotype/genotype study provides platform for rapid execution of Phase 2/3 trial in mGluR+ ADHD adolescent trial • Prevalence rates for mGluR+ mutation in
Slide 5: Development Program Update
NFC - 1 Development Program Update 5
Slide 6: Development Pipeline
Development Pipeline 6 Preclinical Phase 1 Phase 2 Phase 3 NFC - 1 Phenotype/Genotype * (ongoing) mGluR+ ADHD (adolescent, age 12 - 17) mGluR+ ADHD (pediatric, age 6 - 12) ** 22q Deletion Syndrome TARGT CNS Preclinical POC * Non - interventional study to screen and identify ADHD patients for phase 2
Slide 7: ADHD Program
NFC - 1 ADHD Program 7 ADHD Phenotype/Genotype Pediatrics, Adolescents N=1,000+ Design: • Non - interventional • Multi - center (25) • Genotype 1,000+ ADHD subjects, age 6 - 17, identifying patients who are mGluR+ Objectives: • Confirm prevalence of mGluR + • Expedite enrollment in Phase 2/3 interve
Slide 8: ADHD Phenotype/Genotype Study
ADHD Phenotype/Genotype Study 8 CHOP/CAG Biobank ▪ DNA extraction ▪ Genetic Sequencing ▪ BioBanking of DNA Medgenics Database ▪ Evaluation of genotype and phenotype data ▪ Identification of subjects for future trials Saliva Collection ▪ Study site obtains saliva sample and sends to CAG for DNA extra
Slide 9: Phenotype/Genotype Study – Interim Results
• Rapid enrollment - More than 7 00 subjects genotyped in the first 10 weeks at more than 20 US sites - Enrollment to complete in June 2016 • Confirmation of mGluR mutation prevalence - A pproximately 25 % of ADHD patients age 6 - 17 are mGluR + - Validation of previous CAG findings • 95 % of subjec
Slide 10: Phase 2/3 Study in Adolescents with mGluR+ ADHD
Phase 2/3 Study in Adolescents with mGluR + ADHD 10 Phenotype/Genotype • Multi - center: 25 sites • ~150 mGluR+ ADHD subjects: a ge 12 - 17 NFC - 1 • 6 weeks • 1 week follow - up • Objective: – Optimize dose in adolescents, confirm Phase 1B results – Endpoints: ADHD - RS, CGI - I • FPFV June 2016 •
Slide 11: Phase 1/2 Study in 22q Deletion Syndrome
Phase 1/2 S tudy in 22q Deletion Syndrome 11 Open - label Phase • N=30, age 12 - 17 • 5 weeks dose optimization • FPFV: June 2016 • Single center: CHOP Exit Study NFC - 1 Fixed dose 7 weeks • Objective: – Explore symptoms from three neuropsychiatric disorders: ADHD, Anxiety, and Autism Spectrum Diso
Slide 12: mGluR+ ADHD Market Opportunity
mGluR + ADHD Market Opportunity 12
Slide 13: ADHD: Background and Rationale for Genomic Medicine Approach
• Most prevalent neurodevelopmental disorder in children • Highly heritable* (70 %); Heterogeneous, suggesting multiple causes • Early studies, focused on individual genes, failed to identify an underlying cause • Based upon network biology and genotyping, CAG described genetic mutations identifying
Slide 14: ADHD – Current “Fail First” Treatment Paradigm
• Current diagnostic paradigm is symptom - based without objective biomarkers • Current treatment paradigm exposes children to multiple stimulants in a “fail first” approach • Underlying safety concerns create issues with compliance and adherence: – Cardiovascular risk – Growth retardation – Sleep d
Slide 15: Genomic Medicine Approach – Changing the Paradigm
Medgenics’ a pproach selectively targets mGluR+ ADHD patients for treatment with NFC - 1 15 Genomic Medicine Approach – Changing the Paradigm mGluR Genetic Test ADHD Patients (~25%) (~75%) NFC - 1 Other Treatments
Slide 16: Potential for Superior Product Profile
Potential for Superior Product Profile • NFC - 1 clinical profile in mGluR+ ADHD patients – Effective non - stimulant – Non - scheduled – No evidence of growth retardation, addiction, sleep disturbance – No evidence of cardiovascular risk – No expectation for black box warning • Potential to address
Slide 17: mGluR+ ADHD: Market Opportunity
mGluR+ ADHD: Market Opportunity 17 • Overall US ADHD Market – 2015 Sales in excess of $10B * – ~6M pediatric/adolescent patients ** – Stimulants dominate market: 90+% of total prescriptions • mGluR+ ADHD Market, ages 6 - 17 – 1.5M patients ( ~25 % mGluR+) – $2 - 3B market opportunity based upon curr
Slide 18: Financial Update
Financial Update "8 medgenics
Slide 19: Q1 2016 Financial Update
Q1 2016 Financial Update • Gross R&D expenses for the 1 st Quarter were $7.0M increasing from $3.9M for the same period in 2015 – D ue mainly to increased spend on the NFC - 1 program and CHOP collaboration • G&A expenses for the 1 st Quarter were $4.2M increasing from $3.9M for the same period in 2
Slide 20: Upcoming Milestones
Upcoming Milestones 20 PROGRAM TIMING NFC - 1 Complete enrollment in phenotype/genotype study Q2 16 Initiate enrollment in Phase 2/3 mGluR+ ADHD Adolescent Trial Q2 16 Initial top line data H2 16 Initiate enrollment in Phase 1/2 22q Deletion Syndrome Trial* Q2 16 Initial open - label responder data
Slide 21: Summary
Summary • Enthusiastic response to genomic medicine approach from physician community in ADHD • Rapid enrollment into phenotype/genotype study bodes well for initiation of Phase 2/3 trial in June 2016 • T wo significant data readouts expected in 2H 16 – mGluR+ ADHD and 22q Deletion Syndrome (orphan